Theratechnologies Reports Financial Results - Positive Adjusted EBITDA* for Q4 2023 more than doubles from Q3 2023 to $5 million (Net Loss of $2.8 million) leading to a significant turnaround for the full year versus 2022
- Record quarterly revenue of $23.5 million and annual revenue of $81.8 million
- Updated Phase 1 trial investigating sudocetaxel zendusortide in advanced ovarian cancer reaches key milestone with enrollment of first six patients
- Guidance for 2024 set to $87-90 million in annual revenue and a positive Adjusted EBITDA in the range of $13-15 million for the full year 2024
MONTREAL, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today reported business highlights and financial results for the fourth quarter and full year of fiscal year 2023, ended November 30, 2023. All figures are in U.S. dollars unless otherwise stated.
Theratechnologies Reports Financial Results for the Fourth (globenewswire.com)